Pharmacological conditioning for juvenile idiopathic arthritis: a potential solution to reduce methotrexate intolerance.

Abstract

BACKGROUND:

Methotrexate (MTX) therapy has proven to be a successful and safe treatment for Juvenile Idiopathic Arthritis (JIA). Despite the high efficacy rates of MTX, treatment outcomes are often complicated by burdensome gastro-intestinal side effects. Intolerance rates for MTX in children are high (approximately 50%) and thus far no conclusive effective treatment strategies to control for side effects have been found. To address this need, this article proposes an innovative research approach based on pharmacological conditioning, to reduce MTX intolerance.

PRESENTATION OF THE HYPOTHESIS:

A collaboration between medical psychologists, pediatric rheumatologists, pharmacologists and patient groups was set up to develop an innovative research design that may be implemented to study potential improved control of side effects in JIA, by making use of the psychobiological principles of pharmacological conditioning. In pharmacological conditioning designs, learned positive associations from drug therapies (conditioning effects) are integrated in regular treatment regimens to maximize treatment outcomes. Medication regimens with immunosuppressant drugs that made use of pharmacological conditioning principles have been shown to lead to optimized therapeutic effects with reduced drug dosing, which might ultimately cause a reduction in side effects.

TESTING THE HYPOTHESIS:

This research design is tailored to serve the needs of the JIA patient group. We developed a research design in collaboration with an interdisciplinary research group consisting of patient representatives, pediatric rheumatologists, pharmacologists, and medical psychologists.

IMPLICATIONS OF THE HYPOTHESIS:

Based on previous experimental and clinical findings of pharmacological conditioning with immune responses, we propose that the JIA patient group is particularly suited to benefit from a pharmacological conditioning design. Moreover, findings from this study may potentially also be promising for other patient groups that endure long-lasting drug therapies.

• Authors: Rosanne M Smits, Dieuwke S Veldhuijzen, Henriet van Middendorp, Petra C E Hissink Muller, Wineke Armbrust, Elizabeth Legger, Nico M Wulffraat, Andrea W M Evers
• Journal: Pediatric rheumatology online journal (Pediatr Rheumatol Online J) Vol. 18 Issue 1 Pg. 12 (Feb 07 2020) ISSN: 1546-0096 [Electronic] England
• PMID: 32033577 (Publication Type: Journal Article)

Chemical References

• Antirheumatic Agents
• Immunosuppressive Agents
• Methotrexate

Topics

• Animals
• Antirheumatic Agents (adverse effects, therapeutic use)
• Arthritis, Juvenile (drug therapy)
• Drug Tolerance
• Humans
• Immunity (drug effects)
• Immunosuppressive Agents (therapeutic use)
• Methotrexate (adverse effects, therapeutic use)
• Models, Theoretical